EEG-correlates of frontal dysfunction as predictors of relative pharmacoresistance in treatment of endogenous affective disorders

Abstract

Statistically significant correlations have been revealed between initial (before treatment course) values of narrow-band EEG spectral power (mainly of beta activity reflected the frontal lobe dysfunction and hyper-activation of brain stem structures) and quantitative clinical assessments of patient's conditions at remission stage. The data obtained allow to justify the basic considerations on the brain mechanisms of different affective disorders, and to reveal possible neurophysiologic predictors of relative pharmacoresistance (or relatively lower treatment efficacy) in patients with endogenous affective disorders.

Neurobiological parameters in quantitative prediction of treatment outcome in schizophrenic patients

“…In depressive subjects increased EEG beta-1 (13-20 Hz) and beta-2 (20-30 Hz) spectral power values in temporal regions and of alpha-1 (8-9 Hz) all over the scalp were associated with relatively worse treatment outcome [26][27][28]. In subjects with mania, it was increased beta-1 (13-20 Hz) and beta-2 (20-30 Hz) spectral power in frontal regions, and decreased spectral power in 2-13 Hz frequency range all over the scalp [26]. In schizophrenic subjects, it was mainly increased EEG delta (2-4 Hz) spectral power in anterior (frontalcentral-temporal) regions [26].…”

“…In subjects with mania, it was increased beta-1 (13-20 Hz) and beta-2 (20-30 Hz) spectral power in frontal regions, and decreased spectral power in 2-13 Hz frequency range all over the scalp [26]. In schizophrenic subjects, it was mainly increased EEG delta (2-4 Hz) spectral power in anterior (frontalcentral-temporal) regions [26].…”

“…Several recent studies [26][27][28], using several different approaches have been employed by this group to search for EEG predictors of treatment outcome in affective disorders and schizophrenia. They have been directed towards quantitative prediction of treatment outcome by using the values of clinical rating scale scores.…”

“…Appearance of autoantibodies to neuroantigenes (to common myelin protein-AAB CMP and nerve growth factor-AAB NGF -S100B protein) in serum is associated with the most severe and highly aggressive forms of mental disorders reflecting nonreversible changes in brain tissue [33]. Some positive correlations between quantitative clinical assessments and the levels of autoantibodies to AAB CMP and AAB NGF were identified in subjects with depressive-delusional and manic-delusional disorders such as attack-like paranoid schizophrenia [26,35]. Thus, together with the requisite EEG parameters, those immunological parameters that may have predictive value could be combined to form sets of potentially informative neurobiological variables.…”

Multimodal biofeedback for Parkinson’s disease motor and nonmotor symptoms

“…The α and β bands are closely related to motor symptoms of PD [8] and can be used as potential biomarkers to identify motor retardation and stiffness symptoms [9]. PD patients with depressive symptoms can alter δ and θ bands [10] and increase connectivity of frontoparietal networks [11], which can be used to detect nonmotor symptoms. In addition, θ bands are significantly related to emotion regulation ability in PD patients with depression [12, 13].…”